Contact
Revolutionizing IVF: Faster, Cheaper, Healthier
Using the world's most effective
sperm purification device.
Advanced Sperm Selection
Mimics natural processes to identify and isolate high-quality sperm.
In progress
Automated Fertilization
Precision joining of high-quality sperm and egg.
In progress
Automated ICSI
Microinjecting selected sperm into the egg for optimal fertilization.
Results That Matter
+64%
Reduced DNA damage*
+34%
improved morphology*
+23%
blastocyst
formation*
+11%
increase
in motility*
*In bovine studies². Studies with human samples currently in progress.
Our Technology
About Us
XealousBio is a Cornell University spinout, harnessing patented technologies³ developed by a collaboration between Weill Cornell Medicine Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Cornell University College of Agriculture and Life Sciences, and Cornell University College of Veterinary Medicine.
XealousBio is mentored by the Cornell University Center for Life Science Ventures and currently funded by National Science Foundation's Small Business Technology Transfer Phase I Grant⁴.
Contact us at info@xealousbio.com
1. Mean maternal age at giving birth globally is currently 30.9 years old (dotted line, around the age at which mean fertility declines), and increasing, necessitating increased use of ART. Data from The Organisation for Economic Co-operation and Development (OECD). https://www.oecd.org/en/publications/society-at-a-glance-2024_918d8db3-en.html
2. Peer-Reviewed Publication: M. Yaghoobi , A. Abdelhady , A. Favakeh , P. Xie, S. Cheung , A. Mokhtare , Y. L. Lee , A. V. Nguyen , G. Palermo , Z. Rosenwaks , S. H. Cheong and A. Abbaspourrad. Faster sperm selected by rheotaxis leads to superior early embryonic development in vitro, Lab Chip, 2024, 24, 210—223. https://pubs.rsc.org/en/content/articlelanding/2024/lc/d3lc00737e
3. Patent Nos. US11491485B2, US12064766B2, US20240042440A1, WO2024097984A3
4. NSF STTR Phase I: Single-Chip Microfluidic Platform for Finely Controlled In Vitro Fertilization Processes. Award Number: 2304368. Award Amount: $275,000. https://www.nsf.gov/awardsearch/showAward?AWD_ID=2304368
Revolutionizing IVF: Faster, Cheaper, Healthier
Using the world's most effective sperm purification device.
1.0
0.8
0.6
0.4
0.2
30
35
40
0
Relative ertility rate
2024
Age
Women
Men
The Challenges of IVF Today
Manual Assisted Reproductive Therapy (ART) methods are expensive, labor-intensive, and highly dependent on the skill of clinic staff, leading to significant variability in success rates.
As birth ages continue to rise¹, there is an urgent need for more consistent, cost-effective, and efficient solutions to improve fertility outcomes.
Transforming IVF with Biomimicry
Swimtest mimics the “against the current” sperm selection of the female reproductive tract. SwimTest is an advanced sperm purification device designed to enhance IVF outcomes by mimicking natural sperm selection processes.
Our Vision
Building upon the first step of sperm selection, we are developing successive modules using similar microfluidic technologies to automate IVF and ICSI, which would decrease variability in success rates and cost and increase accessibility.
Advanced Sperm Selection
Mimics natural processes to identify and isolate high-quality sperm.
In progress
Automated Fertilization
Precision joining of high-quality sperm and egg.
In progress
Automated ICSI
Microinjecting selected sperm into the egg for optimal fertilization.
Results That Matter
+64%
Reduced DNA damage*
+34%
improved morphology*
+23%
blastocyst
formation*
+11%
increase
in motility*
*In bovine studies². Studies with human samples currently in progress.
Our Technology
About Us
XealousBio is a Cornell University spinout, harnessing patented technologies³ developed by a collaboration between Weill Cornell Medicine Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Cornell University College of Agriculture and Life Sciences, and Cornell University College of Veterinary Medicine.
XealousBio is mentored by the Cornell University Center for Life Science Ventures and currently funded by National Science Foundation's Small Business Technology Transfer Phase I Grant⁴.
Contact us at info@xealousbio.com
1. Mean maternal age at giving birth globally is currently 30.9 years old (dotted line, around the age at which mean fertility declines), and increasing, necessitating increased use of ART. Data from The Organisation for Economic Co-operation and Development (OECD). https://www.oecd.org/en/publications/society-at-a-glance-2024_918d8db3-en.html
2. Peer-Reviewed Publication: M. Yaghoobi , A. Abdelhady , A. Favakeh , P. Xie, S. Cheung , A. Mokhtare , Y. L. Lee , A. V. Nguyen , G. Palermo , Z. Rosenwaks , S. H. Cheong and A. Abbaspourrad. Faster sperm selected by rheotaxis leads to superior early embryonic development in vitro, Lab Chip, 2024, 24, 210—223. https://pubs.rsc.org/en/content/articlelanding/2024/lc/d3lc00737e
3. Patent Nos. US11491485B2, US12064766B2, US20240042440A1, WO2024097984A3
4. NSF STTR Phase I: Single-Chip Microfluidic Platform for Finely Controlled In Vitro Fertilization Processes. Award Number: 2304368. Award Amount: $275,000. https://www.nsf.gov/awardsearch/showAward?AWD_ID=2304368